{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00024906", "CSN": null, "TRF": "ORD_1507970_01", "MRN": "32267086", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1228358", "clinicalId": "1229728", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1507970_01", "SampleName": "US1442542.01", "Version": "0", "Sample": {"FM_Id": "ORD_1507970_01", "SampleId": "US1442542.01", "BlockId": "nan", "TRFNumber": "ORD_1507970_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_11_18", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "Elevated Tumor Fraction Not Detected", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10023", "MRN": "32267086", "FullName": "\u694a\u6e38\u7f8e\u82f1", "FirstName": "Mei_Ying", "LastName": "Yang Yu", "SubmittedDiagnosis": "Metastatic adenocarcinoma", "Gender": "Female", "DOB": "1941_08_31", "OrderingMD": "\u9673\u660e\u6643", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_11_15", "ReceivedDate": "2022-12-02 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Adenocarcinoma, NOS"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "16", "clinicalTrialCount": "3", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ARID1A", "isVUS": "true", "variantName": "A861V"}, {"geneName": "ATM", "isVUS": "true", "variantName": "A1942T"}, {"geneName": "BRCA2", "isVUS": "true", "variantName": "K351R"}, {"geneName": "BRD4", "isVUS": "true", "variantName": "P252S"}, {"geneName": "EGFR", "isVUS": "true", "variantName": "A611T"}, {"geneName": "ERBB2", "isVUS": "true", "variantName": "Q164R"}, {"geneName": "IDH2", "isVUS": "true", "variantName": "R159H"}, {"geneName": "MYCN", "isVUS": "true", "variantName": "F193L"}, {"geneName": "PDGFRA", "isVUS": "true", "variantName": "L761F"}, {"geneName": "STAT3", "isVUS": "true", "variantName": "E616G"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "G12D", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G12D"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870, Loree et al., 2021; 34117033). KRAS mutations have been observed in 91_95% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, cBio_Witkiewicz et al., 2015; 25855536), with the majority of mutations found at codon 12 (Feldmann et al., 2007; 17520196, Rachakonda et al., 2013; 23565280, Hruban et al., 1993; 8342602, Maitra et al., 2006; 16549325). KRAS mutations have been observed with an incidence of 13_50% in cholangiocarcinoma (Hsu et al., 2013; 23335286, Voss et al., 2013; 23391413, Chang et al., 2013; 24372748, Liau et al., 2014; 24406866, O Dell et al., 2012; 22266220, Borger et al., 2012; 22180306, Andersen et al., 2012; 22178589). The reported frequency of KRAS mutations in gallbladder carcinomas is variable, with an incidence ranging from 0 to 38% in different populations (Deshpande et al., 2011; 21303542, Kim et al., 2001; 11410326, Pai and Mojtahed, 2011; 21307665, Rashid et al., 2002; 12374683, Singh et al., 2004; 15242496). KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma (Rachakonda et al., 2013; 23565280). While some studies have reported no association between KRAS mutation and prognosis in cholangiocarcinoma (Borbath et al., 2013; 23975665, Liau et al., 2014; 24406866), other studies have reported an association of KRAS mutation with poorer survival in patients with gallbladder or extrahepatic biliary tract cancers (Javle et al., 2014; 24508317, Malats et al., 1995; 7602358). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). However, Phase 1 and Phase 2 trials of MEK inhibitor monotherapies reported no objective responses (4/4 SD) for patients with biliary tract cancer harboring KRAS mutations (Finn et al., 2018; 29785570, Bekaii_Saab et al., 2011; 21519026). Although a Phase 1/2 study of binimetinib in combination with gemcitabine and cisplatin observed a 33% ORR (1 PR, n=3) for patients with KRAS_mutated advanced biliary tract cancer, this was comparable with the 36% ORR (3 CRs, 9 PRs, n=33) of the overall study population (Lowery et al., 2019; 30563938). One study reported that patients with mutations in the RAS_MAPK pathway may be sensitive to binimetinib and capecitabine; patients with KRAS_, NRAS_, or MEK_mutated gemcitabine_pretreated biliary tract cancer experienced improved mPFS (5.4 vs. 2.6 months, p=0.031), mOS (10.8 vs. 5.3 months, p=0.011), and ORR (40% vs. 12.5%) as compared with patients lacking these mutations (Kim et al., 2018; ASCO Abstract 4079). For patients with pancreatic cancer, MEK inhibitor combinations are under investigation. A Phase 2 study of trametinib with pembrolizumab versus gemcitabine after stereotactic body radiotherapy (SBRT) reported increased median OS (mOS, 14.9 months vs. 12.8 months, HR=0.69) benefit for patients with KRAS_mutated, PD_L1 positive disease (Zhu et al., 2022; 35240087). Combination MEK/autophagy inhibitors are also under investigation based on preclinical evidence of increased autophagy downstream of KRAS_mutated pancreatic tumors (Kinsey et al., 2019; 30833748, Bryant et al., 2019; 30833752). A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine experienced a PR (Kinsey et al., 2019; 30833748). A Phase 2 study of the reoviral agent pelareorep with gemcitabine for patients with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs for 34 patients with a favorable median OS of 10.2 months (Mahalingam et al., 2018; 29799479). A Phase 1b study of second_line pelareorep with pembrolizumab and chemotherapy reported 1 PR of 17.4 months and a DCR of 30% (3/10) (Mahalingham et al., 2020;31694832); an earlier study reported no benefit from pelareorep in combination with paclitaxel/carboplatin (Noonan et al., 2016; 27039845). Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors (Ko et al., 2016; 26251290) or PI3K_AKT pathway inhibitors (LoRusso et al., 2012; ASCO Abstract 2566, Juric et al., 2014; ASCO Abstract 9051, Chung et al., 2017; 27978579, Bedard et al., 2015; 25500057), reported no PRs and frequent adverse events for patients with KRAS_mutated pancreatic cancer. Clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status (Van Laethem et al., 2017; 27975152, Infante et al., 2013; 23583440, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), despite promising results in earlier trials of MEK inhibitor monotherapies (Bodoky et al., 2012; 21594619, Rosen et al., 2008; ASCO Abstract 14585, Rinehart et al., 2004; 15483017, LoRusso et al., 2005; 16009947, Bodoky et al., 2012; 21594619, Infante et al., 2012; 22805291, Weekes et al., 2013; 23434733, Rinehart et al., 2004; 15483017, Infante et al., 2012; 22805291, Garrido_Laguna et al., 2015; 25897431). In a Phase 1 study evaluating the MEK_pan_RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non_small cell lung cancer (NCSLC), 1 with low_grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma (Guo et al., 2020; 33128873). Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS_mutated low_grade serous ovarian cancer and 12% (2/17) for patients with KRAS_mutated non_small cell lung cancer (NSCLC) in a Phase 1 study (Krebs et al., 2021; AACR Abstract CT019, Shinde et al., 2020; AACR Abstract CT143). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors (Hillig et al., 2019; 30683722, Hofmann et al., 2021; 32816843, Gerlach et al., 2020; AACR Abstract 1091). Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations (Hofmann et al., 2021; AACR Abstract CT210, Gort et al., 2020; ASCO Abstract TPS3651).", "Include": "true", "ClinicalTrialNote": "Limited clinical evidence suggests that MEK inhibitors in combination with chemotherapy may be an effective treatment for patients with KRAS_, NRAS_, or MEK_mutated biliary tract cancer. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04941287", "Include": "true"}, {"nctId": "NCT03825289", "Include": "true"}, {"nctId": "NCT04892017", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69_314 months) compared to those with lower TMB (average of 5.7 mutations; 10_42 months) (Hu et al., 2017; ASCO Abstract e15791). In contrast, hypermutated cases were enriched in a poor prognosis subgroup of patients with biliary tract cancer (Nakamura et al., 2015; 26258846). Published data investigating the prognostic implications of bTMB levels in pancreatobiliary carcinoma are limited (PubMed, Jul 2022). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": {"Name": "p16INK4a R80* and p14ARF P94L", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "p16INK4a R80* and p14ARF P94L"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here have been observed in the context of cancer but have not been characterized and their effect on p14ARF function is unclear. CDKN2A/B loss has been reported in 36% of pancreatic ductal carcinomas (Witkiewicz et al., 2015; 25855536). CDKN2A loss has been reported in 25_100% of pancreatic ductal adenocarcinomas analyzed, with a portion of those due to gene deletion (Tsiambas et al., 2007; 17600882, Bergmann et al., 2006; 16497872, Attri et al., 2005; 15985168, Rachakonda et al., 2013; 23565280). CDKN2A mutations and CDKN2A/B homozygous loss have been reported in 2.5_6% and 14% of cholangiocarcinomas, respectively (cBio_Chan_On et al., 2013; 24185513, cBio_Jiao et al., 2013; 24185509). CDKN2A and CDKN2B mutations have been reported in 5.9% and less than 1% of gallbladder carcinomas analyzed in one study (Narayan et al., 2019; 30427539). Homozygous deletion of the CDKN2A locus was reported in 26% of gallbladder carcinomas in one study, while loss of heterozygosity at 9p21 was reported in 57% of samples (Tadokoro et al., 2007; 18081229). Homozygous loss of the chromosomal region 9p21, which contains CDKN2A and CDKN2B, has been reported in 43% (3/7) of biliary dysplasias, as well as in 50% (3/6) of primary sclerosing cholangitis (PSC)_associated cholangiocarcinoma samples, and 50% (8/16) of sporadic cholangiocarcinoma samples (DeHaan et al., 2007; 17239935). In addition, loss of heterozygosity at 9p21 has been found in 89% (8/9) of PSC_associated cholangiocarcinoma samples (Ahrendt et al., 1999; 10334895). However, in another study, homozygous deletion of CDKN2A was reported in 4% (2/51) of cholangiocarcinoma samples (Tannapfel et al., 2002; 12210082). A study of 94 liver fluke_associated cholangiocarcinomas reported loss of p14ARF, p15INK4b, and p16INK4a protein expression in 31%, 58%, and 82% of cases, respectively (Chinnasri et al., 2009; 19200577). Promoter methylation of CDKN2A or CDKN2B affecting the p14ARF, p16INK4a, or p15INK4b loci has been reported in 25_40%, 50_76%, and 49_50% of cholangiocarcinomas, respectively (Tannapfel et al., 2002; 12210082, Klump et al., 2003; 12738733, Chinnasri et al., 2009; 19200577, Yang et al., 2005; 15467712). Promoter methylation of CDKN2A or CDKN2B has been reported in up to 76% of cholangiocarcinomas (Tannapfel et al., 2002; 12210082, Klump et al., 2003; 12738733, Chinnasri et al., 2009; 19200577, Yang et al., 2005; 15467712), 72% of gallbladder adenocarcinomas (Choi et al., 2010; 20422865, Roa et al., 2006; 16699861), and 43% of pancreatic fluid specimens of patients with pancreatic carcinoma (Klump et al., 2003; 12610506). The loss or decrease of p16INK4a expression levels has been reported in 67_80% of pancreatic ductal adenocarcinomas (Oshima et al., 2013; 23470568, Tsiambas et al., 2007; 17600882) and in 35_63% of gallbladder carcinomas (Roa et al., 2006; 16699861, Tadokoro et al., 2007; 18081229, Ma et al., 2005; 15655836). p16INK4a expression has been associated with improved overall survival in pancreatic adenocarcinoma patients in univariate and multivariate analysis (Chang et al., 2010; 20665497). Furthermore, CDKN2A alterations (deletion or mutation) in the presence of concomitant KRAS mutation may correlate with shorter survival in patients with pancreatic ductal adenocarcinoma (Oshima et al., 2013; 23470568). Loss of p16INK4a protein expression has been suggested to serve as a prognostic marker in cholangiocarcinoma, as promoter methylation of CDKN2A and loss of p16INK4a expression have been found to be correlated with poor survival in patients with cholangiocarcinoma (Lee et al., 2002; 12213730, Karamitopoulou et al., 2008; 18854271, Chinnasri et al., 2009; 19200577). Expression of p16INK4a has been found to be correlated with low tumor stage and good prognosis in patients with gallbladder adenocarcinoma (Kim et al., 2013; 24178677). Methylation of the CDKN2A promoter correlated with decreased p16INK4a expression but was not associated with survival in patients with gallbladder cancer (Roa et al., 2006; 16699861). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)(Hu et al., 2018; 29367431, Campbell et al., 2017; 29056344, Pihlak et al., 2018; 29329208, Salem et al., 2018; 29523759, Lahgi et al., 2012; 23029359). MSI_H has been variously reported in 0_42% of gallbladder carcinomas (Moy et al., 2015; 25680569, Mishra et al., 2009; 19866438, Nagahashi et al., 2008; 18176964, Saetta et al., 2006; 15963980, Roa et al., 2005; 15692793, Sessa et al., 2003; 12766614, Rashid et al., 2002; 12374683). MSI_H is infrequent in cholangiocarcinoma, reported in 1% of samples (Javle et al., 2019; ASCO Abstract 4087). A non_zero level of MSI has been reported in 18_49% of cholangiocarcinoma cases (Momoi et al., 2001; 11580146, Limpaiboon et al., 2002; 12175538, Liu et al., 2002; 12402306, Liengswangwong et al., 2003; 14506736), although the studies did not specify what fraction of cases were MSI_H. A higher frequency of MSI (63%) was reported in patients with intrahepatic cholangiocarcinoma associated with exposure to Thorotrast (Liu et al., 2002; 12402306). The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2022). No significant difference in median overall survival or prognosis was found in MSI_H gallbladder carcinomas when compared to MSS cases (Moy et al., 2015; 25680569, Roa et al., 2005; 15692793, Rashid et al., 2002; 12374683). One study reported that MSI is associated with poor prognosis in liver fluke_related cholangiocarcinoma (Limpaiboon et al., 2002; 12175538). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "C242fs*5", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "C242fs*5"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 33_75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, Morton et al., 2010; 20018721, Scarpa et al., 1993; 8494051, Luo et al., 2013; 22782330). Inactivation of p53, through mutation, deletion, or loss of heterozygosity (LOH), has been observed in 25_63% of gallbladder carcinomas and 10_61% of cholangiocarcinomas (Li et al., 2014; 24997986, Ross et al., 2014; 24563076, Jiao et al., 2013; 24185509, Chan_On et al., 2013; 24185513, Borger et al., 2012; 22180306, Suto et al., 2000; 10738270, Ong et al., 2012; 22561520, Javle et al., 2016; 27622582, Nakamura et al., 2015; 26258846, Nault and Zucman_Rossi, 2011; 21538283). TP53 mutations occur more frequently in tumors caused by liver fluke (O. viverrini) infection (40%) than in cholangiocarcinoma cases not related to infection (9%) (Chan_On et al., 2013; 24185513). Additionally, aberrant expression of p53 has been found in 54_81% of pancreatic ductal adenocarcinoma cases (Oshima et al., 2013; 23470568, Ottenhof et al., 2012; 22351431, Tsiambas et al., 2010; 20414934, Scarpa et al., 1993; 8494051). Aberrant TP53 expression, which is indicative of TP53 dysregulation, has been observed in 20\u201362% of gallbladder carcinomas and 25% (5/20) of cholangiocarcinomas (Won et al., 2010; 20955617, Chaube et al., 2006; 16686942, Chuang et al., 2004; 15573254). Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis (Ansari et al., 2011; 21644238, Oshima et al., 2013; 23470568, Grochola et al., 2011; 21404460). Data regarding the prognostic significance of TP53 mutation in cholangiocarcinoma are conflicting (Ruzzenente et al., 2016; 26717940, Xiaofang et al., 2012; 22230750, Ajiki et al., 1996; 8799388, Saetta, 2006; 16724348, Guo et al., 2014; 24746206, Boerner et al., 2021; 33765338, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Churi et al., 2014; 25536104). Overexpression of p53 protein has been associated with reduced patient survival in poorly differentiated gallbladder adenocarcinomas and biliary tract cancers (Lee and Pirdas, 1995; 7567135, Ahrendt et al., 2000; 11180865); however, another study did not find such a correlation (Ajiki et al., 1996; 8799388). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction Not Detected"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "G12D", "Title": "Testing A New Combination of Anti_cancer Immune Therapies, Atezolizumab and CDX_1127 (Varlilumab) With or Without the Addition of A Third Anti_cancer Drug, Cobimetinib, for Advanced_Stage Biliary Tract Cancer", "StudyPhase": "PHASE 2", "Target": "MEK, PD_L1", "Locations": "California, Utah, Colorado, Arizona, Minnesota, Wisconsin, Illinois", "NCTID": "NCT04941287", "Note": "Limited clinical evidence suggests that MEK inhibitors in combination with chemotherapy may be an effective treatment for patients with KRAS_, NRAS_, or MEK_mutated biliary tract cancer. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Utah", "NCTID": "NCT03825289", "Note": "Limited clinical evidence suggests that MEK inhibitors in combination with chemotherapy may be an effective treatment for patients with KRAS_, NRAS_, or MEK_mutated biliary tract cancer. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "A Safety, Tolerability and PK Study of DCC_3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1/2", "Target": "ULK1, ULK2, MEK", "Locations": "Massachusetts, Texas, Pennsylvania", "NCTID": "NCT04892017", "Note": "Limited clinical evidence suggests that MEK inhibitors in combination with chemotherapy may be an effective treatment for patients with KRAS_, NRAS_, or MEK_mutated biliary tract cancer. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "1", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "2", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "3", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "4", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "5", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "6", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "7", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "8", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "9", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "10", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "11", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "12", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "13", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "14", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "15", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "16", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "17", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "18", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "19", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "20", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "21", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "22", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "23", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "24", "ReferenceId": "34117033", "FullCitation": "Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033", "Include": "true"}, {"number": "25", "ReferenceId": "23103869", "FullCitation": "Biankin AV, et al. Nature (2012) pmid: 23103869", "Include": "true"}, {"number": "26", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "27", "ReferenceId": "17520196", "FullCitation": "Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196", "Include": "true"}, {"number": "28", "ReferenceId": "23565280", "FullCitation": "Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280", "Include": "true"}, {"number": "29", "ReferenceId": "8342602", "FullCitation": "Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602", "Include": "true"}, {"number": "30", "ReferenceId": "16549325", "FullCitation": "Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325", "Include": "true"}, {"number": "31", "ReferenceId": "23335286", "FullCitation": "Hsu M, et al. Cancer (2013) pmid: 23335286", "Include": "true"}, {"number": "32", "ReferenceId": "23391413", "FullCitation": "Voss JS, et al. Hum. Pathol. (2013) pmid: 23391413", "Include": "true"}, {"number": "33", "ReferenceId": "24372748", "FullCitation": "Chang YT, et al. J. Gastroenterol. Hepatol. (2014) pmid: 24372748", "Include": "true"}, {"number": "34", "ReferenceId": "24406866", "FullCitation": "Liau JY, et al. Mod. Pathol. (2014) pmid: 24406866", "Include": "true"}, {"number": "35", "ReferenceId": "22266220", "FullCitation": "O Dell MR, et al. Cancer Res. (2012) pmid: 22266220", "Include": "true"}, {"number": "36", "ReferenceId": "22180306", "FullCitation": "Borger DR, et al. Oncologist (2012) pmid: 22180306", "Include": "true"}, {"number": "37", "ReferenceId": "22178589", "FullCitation": "Andersen JB, et al. Gastroenterology (2012) pmid: 22178589", "Include": "true"}, {"number": "38", "ReferenceId": "21303542", "FullCitation": "Deshpande V, et al. BMC Cancer (2011) pmid: 21303542", "Include": "true"}, {"number": "39", "ReferenceId": "11410326", "FullCitation": "Kim YT, et al. Cancer Lett. (2001) pmid: 11410326", "Include": "true"}, {"number": "40", "ReferenceId": "21307665", "FullCitation": "Pai RK, et al. Appl. Immunohistochem. Mol. Morphol. (2011) pmid: 21307665", "Include": "true"}, {"number": "41", "ReferenceId": "12374683", "FullCitation": "Rashid A, et al. Clin. Cancer Res. (2002) pmid: 12374683", "Include": "true"}, {"number": "42", "ReferenceId": "15242496", "FullCitation": "Singh MK, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15242496", "Include": "true"}, {"number": "43", "ReferenceId": "23975665", "FullCitation": "Borbath I, et al. Ann. Oncol. (2013) pmid: 23975665", "Include": "true"}, {"number": "44", "ReferenceId": "24508317", "FullCitation": "Javle M, et al. Hum. Pathol. (2014) pmid: 24508317", "Include": "true"}, {"number": "45", "ReferenceId": "7602358", "FullCitation": "Malats N, et al. J. Clin. Oncol. (1995) pmid: 7602358", "Include": "true"}, {"number": "46", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "47", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "48", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "49", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "50", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "51", "ReferenceId": "29785570", "FullCitation": "Finn RS, et al. Invest New Drugs (2018) pmid: 29785570", "Include": "true"}, {"number": "52", "ReferenceId": "21519026", "FullCitation": "Bekaii_Saab T, et al. J. Clin. Oncol. (2011) pmid: 21519026", "Include": "true"}, {"number": "53", "ReferenceId": "30563938", "FullCitation": "Lowery MA, et al. Clin. Cancer Res. (2019) pmid: 30563938", "Include": "true"}, {"number": "54", "ReferenceId": "35240087", "FullCitation": "Zhu X, et al. Lancet Oncol (2022) pmid: 35240087", "Include": "true"}, {"number": "55", "ReferenceId": "30833748", "FullCitation": "Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748", "Include": "true"}, {"number": "56", "ReferenceId": "30833752", "FullCitation": "Bryant KL, et al. Nat. Med. (2019) pmid: 30833752", "Include": "true"}, {"number": "57", "ReferenceId": "29799479", "FullCitation": "Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479", "Include": "true"}, {"number": "58", "ReferenceId": "31694832", "FullCitation": "Mahalingam D, et al. Clin. Cancer Res. (2019) pmid: 31694832", "Include": "true"}, {"number": "59", "ReferenceId": "27039845", "FullCitation": "Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845", "Include": "true"}, {"number": "60", "ReferenceId": "26251290", "FullCitation": "Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290", "Include": "true"}, {"number": "61", "ReferenceId": "27978579", "FullCitation": "Chung V, et al. JAMA Oncol (2017) pmid: 27978579", "Include": "true"}, {"number": "62", "ReferenceId": "25500057", "FullCitation": "Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057", "Include": "true"}, {"number": "63", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "64", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "65", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "66", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "67", "ReferenceId": "21594619", "FullCitation": "Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619", "Include": "true"}, {"number": "68", "ReferenceId": "15483017", "FullCitation": "Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017", "Include": "true"}, {"number": "69", "ReferenceId": "16009947", "FullCitation": "Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947", "Include": "true"}, {"number": "70", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "71", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "72", "ReferenceId": "25897431", "FullCitation": "Garrido_Laguna I, et al. Oncoscience (2015) pmid: 25897431", "Include": "true"}, {"number": "73", "ReferenceId": "33128873", "FullCitation": "Guo C, et al. Lancet Oncol (2020) pmid: 33128873", "Include": "true"}, {"number": "74", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "75", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "76", "ReferenceId": "30683722", "FullCitation": "Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722", "Include": "true"}, {"number": "77", "ReferenceId": "32816843", "FullCitation": "Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843", "Include": "true"}, {"number": "78", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "79", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "80", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "81", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "82", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "83", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "84", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "85", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "86", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "87", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "88", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "89", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "90", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "91", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "92", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "93", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "94", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "95", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "96", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "97", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "98", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "99", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "100", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "101", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "102", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "103", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "104", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "105", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "106", "ReferenceId": "17600882", "FullCitation": "Tsiambas E, et al. J BUON () pmid: 17600882", "Include": "true"}, {"number": "107", "ReferenceId": "16497872", "FullCitation": "Bergmann F, et al. J. Clin. Pathol. (2006) pmid: 16497872", "Include": "true"}, {"number": "108", "ReferenceId": "15985168", "FullCitation": "Attri J, et al. BMC Gastroenterol (2005) pmid: 15985168", "Include": "true"}, {"number": "109", "ReferenceId": "24185513", "FullCitation": "Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513", "Include": "true"}, {"number": "110", "ReferenceId": "24185509", "FullCitation": "Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509", "Include": "true"}, {"number": "111", "ReferenceId": "30427539", "FullCitation": "Narayan RR, et al. Cancer (2019) pmid: 30427539", "Include": "true"}, {"number": "112", "ReferenceId": "18081229", "FullCitation": "Tadokoro H, et al. World J. Gastroenterol. (2007) pmid: 18081229", "Include": "true"}, {"number": "113", "ReferenceId": "17239935", "FullCitation": "DeHaan RD, et al. Hum. Pathol. (2007) pmid: 17239935", "Include": "true"}, {"number": "114", "ReferenceId": "10334895", "FullCitation": "Ahrendt SA, et al. J. Surg. Res. (1999) pmid: 10334895", "Include": "true"}, {"number": "115", "ReferenceId": "12210082", "FullCitation": "Tannapfel A, et al. J. Pathol. (2002) pmid: 12210082", "Include": "true"}, {"number": "116", "ReferenceId": "19200577", "FullCitation": "Chinnasri P, et al. Hum. Pathol. (2009) pmid: 19200577", "Include": "true"}, {"number": "117", "ReferenceId": "12738733", "FullCitation": "Klump B, et al. Clin. Cancer Res. (2003) pmid: 12738733", "Include": "true"}, {"number": "118", "ReferenceId": "15467712", "FullCitation": "Yang B, et al. Mod. Pathol. (2005) pmid: 15467712", "Include": "true"}, {"number": "119", "ReferenceId": "20422865", "FullCitation": "Choi HJ, et al. Hepatogastroenterology () pmid: 20422865", "Include": "true"}, {"number": "120", "ReferenceId": "16699861", "FullCitation": "Roa JC, et al. J. Gastroenterol. (2006) pmid: 16699861", "Include": "true"}, {"number": "121", "ReferenceId": "12610506", "FullCitation": "Klump B, et al. Br. J. Cancer (2003) pmid: 12610506", "Include": "true"}, {"number": "122", "ReferenceId": "23470568", "FullCitation": "Oshima M, et al. Ann. Surg. (2013) pmid: 23470568", "Include": "true"}, {"number": "123", "ReferenceId": "15655836", "FullCitation": "Ma HB, et al. World J. Gastroenterol. (2005) pmid: 15655836", "Include": "true"}, {"number": "124", "ReferenceId": "20665497", "FullCitation": "Chang DT, et al. Cancer (2010) pmid: 20665497", "Include": "true"}, {"number": "125", "ReferenceId": "12213730", "FullCitation": "Lee S, et al. Am. J. Pathol. (2002) pmid: 12213730", "Include": "true"}, {"number": "126", "ReferenceId": "18854271", "FullCitation": "Karamitopoulou E, et al. Am. J. Clin. Pathol. (2008) pmid: 18854271", "Include": "true"}, {"number": "127", "ReferenceId": "24178677", "FullCitation": "Kim K, et al. Pathol. Oncol. Res. (2014) pmid: 24178677", "Include": "true"}, {"number": "128", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "129", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "130", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "131", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "132", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "133", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "134", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "135", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "136", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "137", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "138", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "139", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "140", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "141", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "142", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "143", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "144", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "145", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "146", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "147", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "148", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "149", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "150", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "151", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "152", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "153", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "154", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "155", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "156", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "157", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "158", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "159", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "160", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "161", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "162", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "163", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "164", "ReferenceId": "26258846", "FullCitation": "Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846", "Include": "true"}, {"number": "165", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "166", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "167", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "168", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "169", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}, {"number": "170", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "171", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "172", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "173", "ReferenceId": "29367431", "FullCitation": "Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431", "Include": "true"}, {"number": "174", "ReferenceId": "29056344", "FullCitation": "Campbell BB, et al. Cell (2017) pmid: 29056344", "Include": "true"}, {"number": "175", "ReferenceId": "29329208", "FullCitation": "Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208", "Include": "true"}, {"number": "176", "ReferenceId": "29523759", "FullCitation": "Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759", "Include": "true"}, {"number": "177", "ReferenceId": "23029359", "FullCitation": "Laghi L, et al. PLoS ONE (2012) pmid: 23029359", "Include": "true"}, {"number": "178", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "179", "ReferenceId": "19866438", "FullCitation": "Mishra PK, et al. Genet. Mol. Res. (2009) pmid: 19866438", "Include": "true"}, {"number": "180", "ReferenceId": "18176964", "FullCitation": "Nagahashi M, et al. World J. Gastroenterol. (2008) pmid: 18176964", "Include": "true"}, {"number": "181", "ReferenceId": "15963980", "FullCitation": "Saetta AA, et al. Exp. Mol. Pathol. (2006) pmid: 15963980", "Include": "true"}, {"number": "182", "ReferenceId": "15692793", "FullCitation": "Roa JC, et al. J. Gastroenterol. (2005) pmid: 15692793", "Include": "true"}, {"number": "183", "ReferenceId": "12766614", "FullCitation": "Sessa F, et al. Diagn. Mol. Pathol. (2003) pmid: 12766614", "Include": "true"}, {"number": "184", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "185", "ReferenceId": "12175538", "FullCitation": "Limpaiboon T, et al. Cancer Lett. (2002) pmid: 12175538", "Include": "true"}, {"number": "186", "ReferenceId": "12402306", "FullCitation": "Liu D, et al. Int. J. Cancer (2002) pmid: 12402306", "Include": "true"}, {"number": "187", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "188", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "189", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "190", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "191", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "192", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "193", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "194", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "195", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "196", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "197", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "198", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "199", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "200", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "201", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "202", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "203", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "204", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "205", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "206", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "207", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "208", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "209", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "210", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "211", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "212", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "213", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "214", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "215", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "216", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "217", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "218", "ReferenceId": "20018721", "FullCitation": "Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018721", "Include": "true"}, {"number": "219", "ReferenceId": "8494051", "FullCitation": "Scarpa A, et al. Am. J. Pathol. (1993) pmid: 8494051", "Include": "true"}, {"number": "220", "ReferenceId": "22782330", "FullCitation": "Luo Y, et al. Pathol. Oncol. Res. (2013) pmid: 22782330", "Include": "true"}, {"number": "221", "ReferenceId": "24997986", "FullCitation": "Li M, et al. Nat. Genet. (2014) pmid: 24997986", "Include": "true"}, {"number": "222", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "223", "ReferenceId": "10738270", "FullCitation": "Suto T, et al. J Surg Oncol (2000) pmid: 10738270", "Include": "true"}, {"number": "224", "ReferenceId": "22561520", "FullCitation": "Ong CK, et al. Nat. Genet. (2012) pmid: 22561520", "Include": "true"}, {"number": "225", "ReferenceId": "27622582", "FullCitation": "Javle M, et al. Cancer (2016) pmid: 27622582", "Include": "true"}, {"number": "226", "ReferenceId": "21538283", "FullCitation": "Nault JC, et al. Semin. Liver Dis. (2011) pmid: 21538283", "Include": "true"}, {"number": "227", "ReferenceId": "22351431", "FullCitation": "Ottenhof NA, et al. Cell Oncol (Dordr) (2012) pmid: 22351431", "Include": "true"}, {"number": "228", "ReferenceId": "20414934", "FullCitation": "Tsiambas E, et al. J BUON () pmid: 20414934", "Include": "true"}, {"number": "229", "ReferenceId": "20955617", "FullCitation": "Won HS, et al. BMC Cancer (2010) pmid: 20955617", "Include": "true"}, {"number": "230", "ReferenceId": "16686942", "FullCitation": "Chaube A, et al. BMC Cancer (2006) pmid: 16686942", "Include": "true"}, {"number": "231", "ReferenceId": "15573254", "FullCitation": "Chuang SC, et al. World J Surg (2004) pmid: 15573254", "Include": "true"}, {"number": "232", "ReferenceId": "21644238", "FullCitation": "Ansari D, et al. Br J Surg (2011) pmid: 21644238", "Include": "true"}, {"number": "233", "ReferenceId": "21404460", "FullCitation": "Grochola LF, et al. Pancreas (2011) pmid: 21404460", "Include": "true"}, {"number": "234", "ReferenceId": "26717940", "FullCitation": "Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940", "Include": "true"}, {"number": "235", "ReferenceId": "22230750", "FullCitation": "Xiaofang L, et al. World J Surg Oncol (2012) pmid: 22230750", "Include": "true"}, {"number": "236", "ReferenceId": "8799388", "FullCitation": "Ajiki T, et al. Hepatogastroenterology () pmid: 8799388", "Include": "true"}, {"number": "237", "ReferenceId": "16724348", "FullCitation": "J Surg Oncol (2006) pmid: 16724348", "Include": "true"}, {"number": "238", "ReferenceId": "24746206", "FullCitation": "Guo R, et al. Hum. Pathol. (2014) pmid: 24746206", "Include": "true"}, {"number": "239", "ReferenceId": "33765338", "FullCitation": "Boerner T, et al. Hepatology (2021) pmid: 33765338", "Include": "true"}, {"number": "240", "ReferenceId": "32020551", "FullCitation": "Conci S, et al. Updates Surg (2020) pmid: 32020551", "Include": "true"}, {"number": "241", "ReferenceId": "29740198", "FullCitation": "Simbolo M, et al. Sci Rep (2018) pmid: 29740198", "Include": "true"}, {"number": "242", "ReferenceId": "25536104", "FullCitation": "Churi CR, et al. PLoS ONE (2014) pmid: 25536104", "Include": "true"}, {"number": "243", "ReferenceId": "7567135", "FullCitation": "Lee CS, et al. Pathology (1995) pmid: 7567135", "Include": "true"}, {"number": "244", "ReferenceId": "11180865", "FullCitation": "Ahrendt SA, et al. J Hepatobiliary Pancreat Surg (2000) pmid: 11180865", "Include": "true"}, {"number": "245", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "246", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "247", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "248", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "249", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "250", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "251", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "252", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "253", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "254", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "255", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "256", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "257", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "258", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "259", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "260", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "261", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "262", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "263", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "264", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "265", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "266", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "267", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "268", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "269", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "270", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "271", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "272", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "273", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "274", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "275", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_11_30 15:37:33", "OpName": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PANCREAS", "disease_ontology": "Pancreatobiliary carcinoma (NOS)", "flowcell_analysis": "2000025016", "gender": "female", "pathology_diagnosis": "Adenocarcinoma", "pipeline_version": "v3.15.0", "purity_assessment": "13.0", "specimen": "ORD_1507970_01*US1442542.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1507970_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1442542.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0033", "cds_effect": "579C>A", "depth": "2449", "equivocal": "false", "functional_effect": "missense", "gene": "MYCN", "percent_reads": "0.33", "position": "chr2:16082765", "protein_effect": "F193L", "status": "unknown", "strand": "+", "transcript": "NM_005378", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.0032", "cds_effect": "5824G>A", "depth": "5880", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "0.32", "position": "chr11:108180948", "protein_effect": "A1942T", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.0012", "cds_effect": "1831G>A", "depth": "8144", "equivocal": "false", "functional_effect": "missense", "gene": "EGFR", "percent_reads": "0.12", "position": "chr7:55233081", "protein_effect": "A611T", "status": "unknown", "strand": "+", "transcript": "NM_005228", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.4877", "cds_effect": "476G>A", "depth": "5485", "equivocal": "false", "functional_effect": "missense", "gene": "IDH2", "percent_reads": "48.77", "position": "chr15:90631877", "protein_effect": "R159H", "status": "unknown", "strand": "_", "transcript": "NM_002168", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.0041", "cds_effect": "723delC", "depth": "6617", "equivocal": "false", "functional_effect": "frameshift", "gene": "TP53", "percent_reads": "0.41", "position": "chr17:7577557", "protein_effect": "C242fs*5", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.5076", "cds_effect": "491A>G", "depth": "6869", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB2", "percent_reads": "50.76", "position": "chr17:37865622", "protein_effect": "Q164R", "status": "unknown", "strand": "+", "transcript": "NM_004448", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.4941", "cds_effect": "2582C>T", "depth": "1524", "equivocal": "false", "functional_effect": "missense", "gene": "ARID1A", "percent_reads": "49.41", "position": "chr1:27089626", "protein_effect": "A861V", "status": "unknown", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "9.0E_4", "cds_effect": "1052A>G", "depth": "6741", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "0.09", "position": "chr13:32906667", "protein_effect": "K351R", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.0021", "cds_effect": "238C>T", "depth": "6304", "equivocal": "false", "functional_effect": "nonsense", "gene": "CDKN2A", "percent_reads": "0.21", "position": "chr9:21971120", "protein_effect": "R80*", "status": "known", "strand": "_", "transcript": "NM_000077", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.0073", "cds_effect": "35G>A", "depth": "3408", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "0.73", "position": "chr12:25398284", "protein_effect": "G12D", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.498", "cds_effect": "2281C>T", "depth": "1239", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "49.8", "position": "chr4:55146607", "protein_effect": "L761F", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.4888", "cds_effect": "754C>T", "depth": "2105", "equivocal": "false", "functional_effect": "missense", "gene": "BRD4", "percent_reads": "48.88", "position": "chr19:15376260", "protein_effect": "P252S", "status": "unknown", "strand": "_", "transcript": "NM_014299", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"allele_fraction": "0.0033", "cds_effect": "1847A>G", "depth": "1207", "equivocal": "false", "functional_effect": "missense", "gene": "STAT3", "percent_reads": "0.33", "position": "chr17:40475063", "protein_effect": "E616G", "status": "unknown", "strand": "_", "transcript": "NM_139276", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "68", "status": "unknown", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"organism": "HPV_6", "reads_per_million": "10", "status": "unknown", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"organism": "HHV_4", "reads_per_million": "82", "status": "unknown", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}, {"organism": "HHV_8", "reads_per_million": "37", "status": "unknown", "dna_evidence": {"sample": "SQ_US1442542.01_1"}}]}}}}}